

August 1, 2002

5641 TO MS 26 A7:26

Office of Special Nutritionals (HFS-450) Center for Food Safety and Applied Nutrition U. S. Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740-3835

BY:----

RE:

Label Claims/Disclaimers

Dear Sir/Madam:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a manufacturer and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	<u>STATEMENTS</u>
Enzymatic Therapy, Inc.	Krebs Magnesium- Potassium Chelates	Magnesium, Potassium	These organic acids are responsible for energy production within every cell of the body.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

Title: Senior Vice President of Scientific Affairs

Date: 8/1/02

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Sincerely,

Chief Financial Officer

975 0162 LET 10864

825 Challenger Drive Green Bay, WI 54311-8328

Ph: 920-469-1313

Fax: 888-570-6460

www.enzy.com

Krebs Magnesium-Potassium Chelates 1e



August 2, 2002

Office of Special Nutritionals (HFS-450) Center for Food Safety and Applied Nutrition U. S. Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740-3835

	EC	EI	₹₩ <u>፲</u> 2002	
Щ	AUG	05	2002	
В	Y:			

RE: Label Claims/Disclaimers

Dear Sir/Madam:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a manufacturer and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Krebs Magnesium- Potassium Chelates	Magnesium, Potassium	Minerals chelated to the Krebs cycle intermediates are better absorbed and utilized.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

Br: FLIGHT

Robert Doster

Title: Senior Vice President of Scientific Affairs

Date: 8/2/02

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Sincerely,

Michael P. Devereux

Chief Financial Officer

825 Challenger Drive Green Bay, WI 54311-8328

> Ph: 920-469-1313 Fax: 888-570-6460

www.enzy.com

Krebs Magnesium-Potassium Chelates 2e